IRIS
RAVELLI, ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 46.117
AS - Asia 4.882
NA - Nord America 1.974
SA - Sud America 369
AF - Africa 104
OC - Oceania 9
Totale 53.455
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 45.163
SG - Singapore 2.276
US - Stati Uniti d'America 1.862
CN - Cina 1.259
VN - Vietnam 772
FR - Francia 440
BR - Brasile 227
HK - Hong Kong 176
FI - Finlandia 117
DE - Germania 94
CH - Svizzera 69
AR - Argentina 60
GB - Regno Unito 60
MX - Messico 60
JP - Giappone 57
IN - India 51
BD - Bangladesh 49
ID - Indonesia 37
NL - Olanda 35
ZA - Sudafrica 32
IQ - Iraq 30
CA - Canada 29
PK - Pakistan 26
PH - Filippine 23
EC - Ecuador 21
CO - Colombia 20
RU - Federazione Russa 19
KE - Kenya 18
TR - Turchia 18
TH - Thailandia 15
IE - Irlanda 14
VE - Venezuela 14
DZ - Algeria 13
ES - Italia 12
SE - Svezia 12
JO - Giordania 11
MA - Marocco 11
CL - Cile 10
RO - Romania 10
PL - Polonia 9
PY - Paraguay 9
OM - Oman 8
UA - Ucraina 8
AU - Australia 7
EG - Egitto 7
KR - Corea 7
RS - Serbia 7
SA - Arabia Saudita 7
TN - Tunisia 7
TW - Taiwan 7
AT - Austria 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
BY - Bielorussia 4
HR - Croazia 4
IR - Iran 4
KZ - Kazakistan 4
LT - Lituania 4
MK - Macedonia 4
NP - Nepal 4
SY - Repubblica araba siriana 4
AM - Armenia 3
AZ - Azerbaigian 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
GT - Guatemala 3
HU - Ungheria 3
IL - Israele 3
KW - Kuwait 3
MM - Myanmar 3
MY - Malesia 3
SI - Slovenia 3
UY - Uruguay 3
UZ - Uzbekistan 3
BE - Belgio 2
CY - Cipro 2
DK - Danimarca 2
GA - Gabon 2
GE - Georgia 2
GM - Gambi 2
JM - Giamaica 2
MD - Moldavia 2
PA - Panama 2
PE - Perù 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TG - Togo 2
AD - Andorra 1
BG - Bulgaria 1
BH - Bahrain 1
BZ - Belize 1
CI - Costa d'Avorio 1
GH - Ghana 1
GR - Grecia 1
HN - Honduras 1
KH - Cambogia 1
LB - Libano 1
Totale 53.438
Salva come PNG Salva come JPEG
Città #
Genova 27.207
Genoa 10.731
Rapallo 4.080
Vado Ligure 2.849
Singapore 1.106
San Jose 678
Ashburn 438
Lauterbourg 400
Ho Chi Minh City 231
Hanoi 174
Hong Kong 169
Beijing 158
Helsinki 112
New York 97
Council Bluffs 91
Bordighera 88
Frankfurt am Main 71
Santa Clara 69
Zurich 67
Tokyo 43
Haiphong 37
Orem 33
Da Nang 32
Mexico City 30
Los Angeles 28
Milan 27
Amsterdam 24
Tianjin 20
Chicago 18
São Paulo 18
City of London 15
Johannesburg 15
Chennai 14
Cardiff 13
Nairobi 13
Biên Hòa 12
Dublin 12
Guangzhou 12
Montreal 12
Baghdad 11
Hải Dương 11
Karachi 11
Naples 11
Rome 11
Shanghai 11
Buffalo 10
Nuremberg 10
Denver 9
Des Moines 9
New Delhi 9
Rio de Janeiro 9
Amman 8
Jakarta 8
Phoenix 8
Thái Nguyên 8
Dallas 7
Muscat 7
Palermo 7
Paris 7
Phủ Lý 7
Poplar 7
Quito 7
Toronto 7
Atlanta 6
Berlin 6
Can Tho 6
Cape Town 6
Guayaquil 6
Hưng Yên 6
London 6
Santiago 6
Valence 6
Warsaw 6
Changsha 5
Houston 5
Istanbul 5
Kyiv 5
Lahore 5
Medellín 5
Ninh Bình 5
Shenzhen 5
Sydney 5
Thái Bình 5
Tân Tiến 5
Belgrade 4
Belo Horizonte 4
Boardman 4
Cairo 4
Caracas 4
Catania 4
Charlotte 4
Curitiba 4
Dammam 4
Delhi 4
Islamabad 4
La Spezia 4
Long Xuyen 4
Manaus 4
Manila 4
Marrakesh 4
Totale 49.633
Salva come PNG Salva come JPEG
Nome #
Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. 269
Novel automated system for Magnetic Resonance Imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. 252
A longitudinal printo study on growth and puberty in juvenile systemic lupus erythematosus. 233
ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study 229
Inactive disease and remission in childhood-onset systemic lupus erythematosus. 227
Juvenile Idiopathic Arthritis: Diagnosis and Treatment 214
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 212
Malattia di Menetrier e gastropatia ipertrofica proteino-disperdente transitoria del bambino: due entità cliniche distinte? 211
Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. 207
HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. 204
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 202
Delineating the application of ultrasound in detecting synovial abnormalities of subtalar joint in juvenile idiopathic arthritis 202
Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. 200
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 199
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 198
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 195
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 195
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 195
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 192
Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. 190
A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. 189

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Assessment of Disease Activity in Patients with Juvenile Idiopathic Arthritis 189
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 187
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 186
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 185
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis 181
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 181
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 181
Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. 180
Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. 180
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 179
A positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. 178
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 177
Comparison of clinical versus ultrasound determined synovitis in juvenile idiopathic arthritis. 176
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis 176
Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis. 176
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. 175
Should children and adolescents with systemic lupus erythematosus be given statin therapy to prevent early atherosclerosis? 175
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 175
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 174
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 173
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. 172
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 172
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 171
Advances in biomarkers for paediatric rheumatic diseases 171
Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. 170
Clinical outcome measures in juvenile idiopathic arthritis 170
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 170
Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. 169
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases 168
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 168
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 167
Type I interferon pathway activation in COPA syndrome 167
Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis. 165
Advances and challenges in imaging in juvenile idiopathic arthritis. 164
Preliminary definition of improvement in juvenile arthritis. 163
Aortic valve regurgitation as the presenting sign of Takayasu arteritis. 163
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 162
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. 162
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. 162
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 162
Antiphospholipid antibody syndrome in pediatric patients. 161
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 161
Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. 161
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 161
Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. 160
Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations 160
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis 160
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 159
Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. 159
Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. 159
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 159
Antinuclear antibody positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. 158
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 157
Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016 157
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial 156
Criteria to define response to therapy in paediatric rheumatic diseases. 155
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 155
Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era 155
Patterns of clinical remission in select categories of juvenile idiopathic arthritis 154
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 154
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. 154
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. 154
Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis 154
High prevalence of antiphospholipid antibodies in children with idiopatic cerebral ischemia 153
Recent therapeutic advances in juvenile idiopathic arthritis 153
Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. 153
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. 152
Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. 152
A new short and simple health-related quality of life measure for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis 152
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 152
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. 152
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases 152
Adapted versions of the Sharp-van Der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 151
Chronic recurrent multifocal osteomyelitis with unusual features. 151
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. 151
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 150
Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. 150
Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis 150
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 150
Totale 17.384
Salva come PNG Salva come JPEG
Categoria #
all - tutte 177.780
article - articoli 174.575
book - libri 0
conference - conferenze 297
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.908
Totale 355.560
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021884 0 0 0 0 0 0 0 0 0 378 216 290
2021/20224.959 140 373 514 349 315 194 364 1.132 202 448 290 638
2022/20234.919 523 307 56 386 815 875 39 490 903 41 412 72
2023/20242.366 143 382 48 264 218 351 133 148 98 80 120 381
2024/20257.273 173 635 313 444 806 762 695 1.194 319 434 624 874
2025/202611.871 1.497 415 754 905 1.867 1.396 2.199 658 1.064 1.116 0 0
Totale 54.413